Himalaya Nutravedics India IPO Details

Bookbuilding IPO | ₹26 Cr | Listing at BSE SME | Tue, Sep 22, 2026 - Thu, Sep 24, 2026

Himalaya Nutravedics IPO is a book build issue of ₹26.50 crores. The issue is entirely a fresh issue of 25.00 lakh shares of ₹26.50 crore.

Himalaya Nutravedics IPO opens for subscription on Sep 22, 2026 and closes on Sep 24, 2026. The allotment for the Himalaya Nutravedics IPO is expected to be finalized on Sep 25, 2026. Himalaya Nutravedics IPO will list on the BSE SME with a tentative listing date fixed as Sep 29, 2026.

Himalaya Nutravedics IPO is set issue price band at ₹100 to ₹106 per share. The lot size for an application is 1,200 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,54,400 (2,400 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,600 shares), amounting to ₹3,81,600.

Nirbhay Capital Services Pvt.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. The Market Maker of the company is Allwin Securities Ltd.

Refer to Himalaya Nutravedics IPO RHP for detailed Information.

IPO Open

Tue, Sep 22, 2026

IPO Close

Thu, Sep 24, 2026

Price Band

₹100 to ₹106

Market Cap*

₹93.35 Cr * on Upper Price

IPO Details

IPO Date

22 to 24 Sep, 2026
Listing Date

Mon, Sep 28, 2026
Face Value

₹10 per share
Price Band

₹100 to ₹106
Lot Size

1,200 Shares
Sale Type

Fresh capital only
Issue Type

Bookbuilding IPO
Listing At

BSE SME

Total Issue Size

24,99,600 shares (agg. up to ₹26 Cr)
Reserved for Market Maker

1,26,000 shares (agg. up to ₹1 Cr) Allwin Securities Ltd.
Fresh Issue (Ex Market Maker)

23,73,600 shares (agg. up to ₹25 Cr)
Net Offered to Public

23,73,600 shares (agg. up to ₹25 Cr)
Share Holding Pre Issue

63,06,720 shares
Share Holding Post Issue

88,06,320 shares

IPO Open

Tue, Sep 22, 2026
Allotment

Fri, Sep 25, 2026
Credit of Shares

Mon, Sep 28, 2026

IPO Close

Thu, Sep 24, 2026
Refund

Mon, Sep 28, 2026
Listing

Tue, Sep 29, 2026

Issue Reservation

Himalaya Nutravedics IPO comprises a total issue size of 24,99,600 shares. The net offer to the public is 23,73,600 shares, after excluding 1,26,000 shares allotted on a firm basis. Of the Net offer 11,84,400 (49.90%) are allocated to QIB, 3,56,400 (15.02%) allocated to NII 8,32,800 (35.09%) allocated to RII.

Investor Category	Shares	% of Net Issue	% of Total Issue
QIB	11,84,400	49.90%	47.38%
− Anchor Investor	7,10,400		28.42%
− QIB (Ex. Anchor)	4,74,000		18.96%
NII (HNI)	3,56,400	15.02%	14.26%
− bNII > ₹10L	2,37,600		9.51%
− sNII < ₹10L	1,18,800		4.75%
Retail	8,32,800	35.09%	33.32%
Firm Reservations
Market Maker	1,26,000		5.04%
Total	24,99,600	100.00%	100.00%

IPO Lot Size

Investors can bid for a minimum of 2,400 shares and in multiples of 1,200 shares thereof.

Application	Lots	Shares	Amount
Individual investors (IND) (Min)	2	2400	₹2,54,400
Individual investors (IND) (Max)	2	2400	₹2,54,400
S-HNI (Min)	3	3600	₹3,81,600
S-HNI (Max)	7	8400	₹8,90,400
B-HNI (Min)	8	9600	₹10,17,600

About Himalaya Nutravedics India Ltd.

Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. The Company manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements. Its products are available in multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. The products cater to therapeutic and wellness areas such as gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, women’s wellness and general wellness.

Himalaya Nutravedics operates through a hybrid business model comprising its own branded products and third-party contract manufacturing. Under its own-brand business, the Company develops, manufactures and markets Ayurvedic and nutraceutical products, while its third-party manufacturing business provides formulation, manufacturing, packaging and dispatch services based on client specifications. As of March 31, 2026, its own-brand business contributed approximately ₹2,202.54 lakh, representing about 51.14% of total revenue.

The Company operates an integrated manufacturing facility in Hyderabad, Telangana, where formulation, production, quality control, packaging and finished-goods release are carried out internally. The facility is compliant with WHO-GMP standards and holds registrations and licences from AYUSH and FSSAI, along with certifications including ISO 9001:2015, ISO 22000:2018, HACCP, HALAL and KOSHER.

As of July 31, 2026, the Company had 86 full-time employees across marketing, factory, finance, quality, compliance and administration functions.

Competitive Strengths

Geographic expansion across India.
Long-standing supplier and customer relationships.
Integrated multi-dosage manufacturing capabilities.
Doctor acceptance supported by product performance.
Broad therapeutic coverage across Ayurvedic and nutraceutical segments

Company Financials (Restated Consolidated)

Himalaya Nutravedics India Ltd.’s revenue increased by 105% and profit after tax (PAT) rose by 231% between the financial year ending with March 31, 2026 and March 31, 2025. (Amount in ₹ Crore)

Period Ended	31 Mar 2026	31 Mar 2025	31 Mar 2024
Assets	24.42	10.82	6.09
Total Income	43.12	21.00	14.43
Profit After Tax	7.39	2.23	0.43
EBITDA	8.10	2.99	0.94
NET Worth	16.38	6.75	1.34
Reserves and Surplus	10.07	2.76	0.53
Total Borrowing	5.13	1.76	3.24

Recently Listed IPOs in Other Food Products

Company	Issue Type	Issue Size	Issue Price	PE Ratio	Listing Day Close	Listing Gain/Loss %	LTP
Elfin Agro India Ltd.	SME	₹25.03 Cr	₹47	13.05	₹47.60	+1.28%	₹93.90
Shyam Dhani Industries Ltd.	SME	₹38.49 Cr	₹70	13.19	₹139.65	+99.50%	₹52.10
Pajson Agro India Ltd.	SME	₹74.45 Cr	₹118	10.11	₹130.20	+10.34%	₹212.00

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

# Issue Objects

Est Amt (₹ Cr.)
1 Funding Working Capital Requirements

13.75
2 Business Development and Digital Marketing Activities

7.50
3 General Corporate Purposes
Total

21.25

Key Performance Indicator (KPI)

KPI	Mar 31, 2026
ROE	63.87%
ROCE	36.41%
Debt/Equity	0.31
RoNW	45.12%
PAT Margin	17.16%
EBITDA Margin	18.82%
NAV	26.70
Price to Book Value	3.97

IPO Valuation

Valuation Metric	Pre IPO	Post IPO
EPS (₹)	11.72	8.39
P/E (x)	9.04	12.63
Market Cap at Offer Price	₹66.85 Cr.	₹93.35 Cr

The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue
The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2026 available in RHP.
The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of March 31, 2026 available in RHP.

Shareholding Structure

Category	Pre IPO	Post IPO
Promoter and Promoter Group	95.14%	68.13%
Public	4.86%	31.87%
Total	100%	100%

Company Promoters: Rohit Asawa, Divya Asawa, Chanda Asawa and Rama Raju Penmatsa.

Himalaya Nutravedics IPO Recommendations

Review By	Subscribe	May Apply	Neutral	Avoid
Brokers	0	0	0	0
Members	0	0	0	0

IPO Registrar

Kfin Technologies Ltd.

040-79615565
himalaya.ipo@kfintech.com
Visit Website

IPO Lead Manager(s)

Nirbhay Capital Services Pvt.Ltd.

Lead Manager Reports

Lead Manager Performance Summary
Lead Manager Performance Tracker

Contact Details

Himalaya Nutravedics India Ltd. Address

Plot No. 101/A, Phase-III

Industrial Development Park

Cherlapally, Hindustan Cables Ltd, Uppal

Hyderabad, Telangana, 500051

+91-9063498493
info@himalayanutravedics.com
Visit Website

IPO FAQs

What is the Himalaya Nutravedics IPO?

Himalaya Nutravedics IPO is a SME IPO of 24,99,600 equity shares of the face value of ₹10 aggregating up to ₹26 Crores. The issue is priced at ₹100 to ₹106. The minimum order quantity is 1200.

The IPO opens on Tue, Sep 22, 2026, and closes on Thu, Sep 24, 2026.

Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.

How to apply in Himalaya Nutravedics IPO through Angel One?

Angel One customers can apply online in Himalaya Nutravedics IPO using UPI as a payment gateway. Angel One customers can apply in Himalaya Nutravedics IPO by login into Angel One Console (back office) and submitting an IPO application form.

Steps to apply in Himalaya Nutravedics IPO through Angel One

Visit the Angel One website and login to Console.
Go to Portfolio and click the IPOs link.
Go to the ‘Himalaya Nutravedics IPO’ row and click the ‘Bid’ button.
Enter your UPI ID, Quantity, and Price.
Submit IPO application form.
Visit the UPI App (net banking or BHIM) to approve the mandate.
Visit Angel One IPO Application Process Review for more detail.

When Himalaya Nutravedics IPO will open?

The Himalaya Nutravedics IPO opens on Tue, Sep 22, 2026 and closes on Thu, Sep 24, 2026.

What is the lot size of Himalaya Nutravedics IPO?

Himalaya Nutravedics IPO lot size is 1200, and the minimum amount required for application is ₹2,54,400, with 2 lots being the minimum application size.

How to apply for Himalaya Nutravedics IPO?

You can apply in Himalaya Nutravedics IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don’t offer banking services. Read more detail about applying IPO online through Angel One, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

When is Himalaya Nutravedics IPO allotment?

The finalization of Basis of Allotment for Himalaya Nutravedics IPO will be done on Friday, September 25, 2026, and the allotted shares will be credited to your demat account by Mon, Sep 28, 2026. Check the Himalaya Nutravedics IPO allotment status.

When is Himalaya Nutravedics IPO listing date ?

The Himalaya Nutravedics IPO listing date is not yet announced. The tentative date of listing is Tue, Sep 29, 2026.